Drug Profile

KB 707

Alternative Names: KB-707

Latest Information Update: 23 Dec 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Krystal Biotech
Class Antineoplastics; Gene therapies; Immunotherapies
Mechanism of Action Gene transference; Immunologic cytotoxicity; Interleukin 12 replacements; Interleukin 2 replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase I/II Lung cancer; Solid tumours

Most Recent Events

18 Dec 2024 Adverse events and efficacy data from phase I KYANITE-1 trials in lung cancer released by Krystal Biotech
05 Aug 2024 US FDA approves Rare Pediatric Disease Designation for osteosarcoma
13 Feb 2024 KB 707 receives Fast Track designation for Lung cancer [Inhalation,Aerosol] (Late-stage disease, Monotherapy, Second-line therapy or greater) in USA

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com